BULIMIA NERVOSA TREATMENT MARKET ANALYSIS

Bulimia Nervosa Treatment Market, by Treatment Type (Drug Treatment (Selective Serotonin Reuptake Inhibitor, Serotonin-Norepinephrine Reuptake Inhibitor, Benzodiazepines, Tricyclic Antidepressants, and Others) and Non-drug Treatment (Nutritional Therapy, Behavioral Therapy, and Others)), by Route of Administration (Oral, Intravenous, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Dec 2020
Code : CMI4323
Pages :156
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Global Bulimia Nervosa Treatment Market – Restraints

Lack of proper reimbursement policies for the treatment of eating disorders is expected to restrain growth of the global bulimia nervosa treatment market over the forecast period. For instance, according to the National Eating Disorders Associations, per year, in the U.S., the total treatment cost for the eating disorders is valued at US$ 30,000 per patient. Even in the presence of insurance, the patients has to shell out more money for the treatment. Moreover, according to the same source, in the U.S., there were approximately 54,000 emergency department admissions and 23,500 in-patient hospitalizations visits due to eating disorders in the year span of 2018 – 2019, costing around US$ 29 million and US$ 209 million respectively.

Furthermore, lack of drugs specifically for the treatment of bulimia nervosa treatment and lack of awareness regarding the treatment options among the population are the factors that are expected to restrain growth of the global bulimia nervosa treatment market over the forecast period.

Bulimia Nervosa Treatment Market Report Snapshots